- Home
- VCEL vs CMMB Comparison
VCEL vs CMMB Comparison
Compare VCEL & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- CMMB
- Stock Information
- Founded
- VCEL 1989
- CMMB 2004
- Country
- VCEL United States
- CMMB Israel
- Employees
- VCEL N/A
- CMMB N/A
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- VCEL Health Care
- CMMB Health Care
- Exchange
- VCEL Nasdaq
- CMMB Nasdaq
- Market Cap
- VCEL 2.1B
- CMMB 23.0M
- IPO Year
- VCEL 1997
- CMMB N/A
- Fundamental
- Price
- VCEL $40.25
- CMMB $1.16
- Analyst Decision
- VCEL Strong Buy
- CMMB Strong Buy
- Analyst Count
- VCEL 8
- CMMB 2
- Target Price
- VCEL $62.00
- CMMB $8.50
- AVG Volume (30 Days)
- VCEL 477.0K
- CMMB 182.0K
- Earning Date
- VCEL 07-31-2025
- CMMB 08-20-2025
- Dividend Yield
- VCEL N/A
- CMMB N/A
- EPS Growth
- VCEL 521.85
- CMMB N/A
- EPS
- VCEL 0.05
- CMMB N/A
- Revenue
- VCEL $238,541,000.00
- CMMB N/A
- Revenue This Year
- VCEL $23.03
- CMMB N/A
- Revenue Next Year
- VCEL $24.52
- CMMB N/A
- P/E Ratio
- VCEL $780.58
- CMMB N/A
- Revenue Growth
- VCEL 14.80
- CMMB N/A
- 52 Week Low
- VCEL $37.39
- CMMB $0.87
- 52 Week High
- VCEL $63.00
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- VCEL 44.06
- CMMB 38.60
- Support Level
- VCEL $39.39
- CMMB $1.17
- Resistance Level
- VCEL $42.61
- CMMB $1.20
- Average True Range (ATR)
- VCEL 1.73
- CMMB 0.05
- MACD
- VCEL -0.15
- CMMB 0.00
- Stochastic Oscillator
- VCEL 24.16
- CMMB 16.46
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.